Browse > Article
http://dx.doi.org/10.4062/biomolther.2021.122

Lipid Metabolism, Disorders and Therapeutic Drugs - Review  

Natesan, Vijayakumar (Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University)
Kim, Sung-Jin (Department of Pharmacology and Toxicology, Metabolic Diseases Research Laboratory, School of Dentistry, Kyung Hee University)
Publication Information
Biomolecules & Therapeutics / v.29, no.6, 2021 , pp. 596-604 More about this Journal
Abstract
Different lifestyles have an impact on useful metabolic functions, causing disorders. Different lipids are involved in the metabolic functions that play various vital roles in the body, such as structural components, storage of energy, in signaling, as biomarkers, in energy metabolism, and as hormones. Inter-related disorders are caused when these functions are affected, like diabetes, cancer, infections, and inflammatory and neurodegenerative conditions in humans. During the Covid-19 period, there has been a lot of focus on the effects of metabolic disorders all over the world. Hence, this review collectively reports on research concerning metabolic disorders, mainly cardiovascular and diabetes mellitus. In addition, drug research in lipid metabolism disorders have also been considered. This review explores lipids, metabolism, lipid metabolism disorders, and drugs used for these disorders.
Keywords
Lipid metabolism; Disorders; Diabetes; Cardiovascular disorder; Drugs;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Solomon, M. and Muro, S. (2017) Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv. Drug Deliv. Rev. 118, 109-134.   DOI
2 Song, X., Zhong, L., Lyu, N., Liu, F., Li, B., Hao, Y., Xue, Y., Li, J., Feng, Y., Ma, Y., Hu, Y. and Zhu, B. (2019) Inulin can alleviate metabolism disorders in ob/ob mice by partially restoring leptin-related pathways mediated by gut microbiota. Genomics Proteomics Bioinformatics 17, 64-75.   DOI
3 Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R. and Raal, F. J. (2013) Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120.   DOI
4 Xiao, C., Rossignol, F., Vaz, F. M. and Ferreira, C. R. (2021) Inherited disorders of complex lipid metabolism: a clinical review. J. Inherit. Metab. Dis. 44, 809-825.   DOI
5 Dibaise, J. K., Zhang, H., Crowell, M. D., Krajmalnik-Brown, R., Decker, G. A. and Rittmann, B. E. (2008) Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 4, 460-469.
6 Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P. and Mirza, W. (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front. Endocrinol. 8, 6.
7 Coppens, I., Asai, T. and Tomavo, S. (2014) Chapter 8 - Biochemistry and metabolism of Toxoplasma gondii: carbohydrates, lipids and nucleotides. In Toxoplasma Gondii (2nd ed.) (L. M. Weiss and K. Kim, Eds.), pp. 257-295. Academic Press.
8 Denisenko, Y. K., Kytikova, O. Y., Novgorodtseva, T. P., Antonyuk, M. V., Gvozdenko, T. A. and Kantur, T. A. (2020) Lipid-induced mechanisms of metabolic syndrome. J. Obes. 2020, 5762395.
9 Fernandez, L. P., Gomez, de Cedron, M., Ramirez de Molina, A. (2020) Alterations of lipid metabolism in cancer: implications in prognosis and treatment. Front. Oncol. 10, 577420.   DOI
10 Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., Corella, D., Aros, F., Gomez-Gracia, E., Ruiz-Gutierrez, V., Fiol, M., Lapetra, J., Lamuela-Raventos, R. M., Serra-Majem, L., Pinto, X., Basora, J., Munoz, M. A., Sorli, J. V., Martinez, J. A., and Martinez-Gonzalez, M. A. (2013) Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med 368,1279-1290.   DOI
11 Frayn, K. N., Coppack, S. W., Humphreys, S. M., Clark, M. L. and Evans, R. D. (1993) Periprandial regulation of lipid metabolism in insulin-treated diabetes mellitus. Metabolism 42, 504-510.   DOI
12 McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M. and Duell, P. B. (2019) Diagnosis and treatment of heterozygous familial hypercholesterolemia. J. Am. Heart Assoc. 8, e013225.   DOI
13 Tian, L. and Yu, X. (2015) Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (review). Mol. Med. Rep. 12, 783-794.   DOI
14 Bagger, Y. Z., Tanko, L. B., Alexandersen, P., Qin, G. and Christiansen, C.; Prospective epidemiological risk factors study group (2006) Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med. 259, 598-605.   DOI
15 Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgozoglu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F., Marz, W., Newman, C. B., Wiklund, O., Jacobson, T. A., Catapano, A. L., Chapman, M. J. and Ginsberg, H. N.; European Atherosclerosis Society Consensus Panel (2015) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012-1022.   DOI
16 Tracey, T. J., Steyn, F. J., Wolvetang, E. J. and Ngo, S. T. (2018) Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front. Mol. Neurosci. 11, 10.   DOI
17 Trebaticka, J., Dukat, A., Durackova, Z. and Muchova, J. (2017) Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids. Physiol. Res. 66, 363-382.
18 Stone, N. J. (1994) Secondary causes of hyperlipidemia. Med. Clin. North Am. 78, 117-141.   DOI
19 Catapano, A. L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M. R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M., Durrington, P., Erdine, S., Halcox, J., Hobbs, R., Kjekshus, J., Filardi, P. P., Riccardi, G., Storey, R. F. and Wood, D.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS) (2011) ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217, 3-46.   DOI
20 Kromhout, D., Giltay, E. J. and Geleijnse, J. M.; Alpha Omega Trial Group (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363, 2015-2026.   DOI
21 Verma, N. (2017) Introduction to hyperlipidemia and its treatment: a review. Int. J. Curr. Pharm. Res. 9, 6-14.   DOI
22 Azhar, S. (2010) Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 6, 657-691.   DOI
23 Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., Huang, F., Xue, A., Albizem, M., Scott, R. and Stein, E. A. (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63, 1278-1288.   DOI
24 Taskinen, M. R., Lahdenpera, S. and Syvanne, M. (1996) New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann. Med. 28, 335-340.   DOI
25 Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., Van Veldhoven, P. P., Waltregny, D., Daniels, V. W., Machiels, J., Vanderhoydonc, F., Smans, K., Waelkens, E., Verhoeven, G. and Swinnen, J. V. (2010) De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 8117-8126.   DOI
26 Yuan, G., Al-Shali, K. Z. and Hegele, R. A. (2007) Hypertriglyceridemia: its etiology, effects and treatment. Can. Med. Assoc. J. 176, 1113-1120.   DOI
27 Ophardt, C. E. (2003) Overview of lipid function. In Virtual ChemBook. Elmhurst College. Available from: http://chemistry.elmhurst.edu/vchembook/620fattyacid.html/.
28 Yue, S., Li, J., Lee, S. Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L. and Cheng, J. X. (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19, 393-406.   DOI
29 Pischon, T., Nothlings, U. and Boeing, H. (2008) Obesity and cancer. Proc. Nutr. Soc. 67, 128-145.   DOI
30 Ratnayake, W. M. N. and Galli, C. (2009) Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann. Nutr. Metab. 55, 8-43.   DOI
31 Shattat, G. F. A. (2014) Review article on hyperlipidemia: types, treatments and new drug targets. Biomed. Pharmacol. J. 7, 399-409.   DOI
32 Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A. and Skene, A. M.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504.   DOI
33 Dias, S., Paredes, S. and Ribeiro, L. (2018) Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue. Int. J. Endocrinol. 4, 2637418.
34 Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid classification, structures and tools. Biochim. Biophy. Acta 1811, 637-647.   DOI
35 Natesan, V. and Kim, S. J. (2021) Diabetic nephropathy - a review of risk factors, progression, mechanism, and dietary management. Biomol. Ther. (Seoul) 29, 365-372.   DOI
36 Lattimer, J. M. and Haub, M. D. (2010) Effects of dietary fiber and its components on metabolic health. Nutrients 2, 1266-1289.   DOI
37 Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E. and Manson, J. E. (2016) Cardiovascular disease in women: clinical perspectives. Circ. Res. 118, 1273-1293.   DOI
38 Ahmed, S., Shah, P. and Ahmed, O. (2021) Biochemistry, lipids. In: StatPearls, pp. 11-19. StatPearls Publishing, Treasure Island.
39 Alves-Bezerra, M. and Cohen, D. E. (2017) Triglyceride metabolism in the liver. Compr. Physiol. 8, 1-8.
40 Alwarawrah, Y., Hughes, P., Loiselle, D., Carlson, D. A., Darr, D. B., Jordan, J. L., Xiong, J., Hunter, L. M., Dubois, L. G., Thompson, J. W., Kulkarni, M. M., Ratcliff, A. N., Kwiek, J. J. and Haystead, T. A. (2016) Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer. Cell Chem. Biol. 23, 678-688.   DOI
41 Nilsson, P. M., Tuomilehto, J. and Ryden, L. (2019) The metabolic syndrome - what is it and how should it be managed? Eur. J. Prev. Cardiol. 26, 33-46.   DOI
42 Novgorodtseva, T. P., Karaman, Y. K., Zhukova, N. V., Lobanova, E. G., Antonyuk, M. V. and Kantur, T. A. (2011) Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids Health Dis. 10, 82.   DOI
43 Pahan, K. (2006) Lipid-lowering drugs. Cell. Mol. Life Sci. 63, 1165-1178.   DOI
44 Parhofer, K. G. (2016) The treatment of disorders of lipid metabolism. Dtsch. Arztebl. Int. 113, 261-268.
45 Athenstaedt, K. and Daum, G. (2006) The life cycle of neutral lipids: synthesis, storage and degradation. Cell. Mol. Life Sci. 63, 1355-1369.   DOI
46 Amalan, V. and Vijayakumar, N. (2015) Antihyperglycemic effect of p-coumaric acid on streptozotocin induced diabetic rats. Indian J. Appl. Res. 5, 10-13.
47 Amalan, V., Vijayakumar, N. and Ramakrishnan, A. (2015) P-Coumaric acid regulates blood glucose and antioxidant levels in streptozotocin induced diabetic rats. J. Chem. Pharm. Res. 7, 831-839.
48 Arumugam, R. and Natesan, V. (2017) Urea cycle pathway targeted therapeutic action of naringin against ammonium chloride induced hyperammonemic rats. Biomed. Pharmacother. 94, 1028-1037.   DOI
49 Bazinet, R. P. and Laye, S. (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 15, 771-785.   DOI
50 Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H., Jr., Murphy, R. C., Russell, D. W., Seyama, Y., Shaw, W., Shimizu, T., Spener, F., van Meer, G., VanNieuwenhze, M. S., White, S. H., Witztum, J. L. and Dennis, E. A. (2005) A comprehensive classification system for lipids. J. Lipid Res. 46, 839-861.   DOI
51 Fredrickson, D. S. and Lees, R. S. (1965) Editorial: a system for phenotyping hyperlipoproteinemia. Circulation 31, 321-327.   DOI
52 Goldberg, I. J., Trent, C. M. and Schulze, P. C. (2012) Lipid metabolism and toxicity in the heart. Cell Metab. 15, 805-812.   DOI
53 Huang, C. and Freter, C. (2015) Lipid metabolism, apoptosis and cancer therapy. Int. J. Mol. Sci. 16, 924-949.   DOI
54 Joynt, K. E., Whellan, D. J. and Oconnor, C. M. (2003) Depression and cardiovascular disease: mechanisms of interaction. Biol. Psychiatry 54, 248-261.   DOI
55 Castle, J. C., Hara, Y., Raymond, C. K., Garrett-Engele, P., Ohwaki, K., Kan, Z., Kusunoki, J. and Johnson, J. M. (2009) ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus. PLoS ONE 4, e4369.   DOI
56 Waller, J. R. and Waller, D. G. (2014) Drugs for lipid disorders, antiplatelet drugs and fibrinolytics. Medicine 42, 544-548.   DOI
57 Wu, L., Piotrowski, K., Rau, T., Waldmann, E., Broedl, U. C., Demmelmair, H., Koletzko, B., Stark, R. G., Nagel, J. M., Mantzoros, C. S. and Parhofer, K. G. (2014) Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism 63, 382-391.   DOI
58 Yan, J. and Horng, T. (2020) Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 30, 979-989.   DOI
59 Burdon, K. P., Langefeld, C. D., Beck, S. R., Wagenknecht, L. E., Carr, J. J., Freedman, B. I., Herrington, D. and Bowden, D. W. (2005) Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study. J. Med. Genet. 42, 720-724.   DOI
60 Butte, N. F. (2000) Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am. J. Clin. Nutr. 71, 1256S-1261S.   DOI
61 Glass, C. K. and Olefsky, J. M. (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635-645.   DOI
62 Grundy, S. M. (2009) Advancing drug therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 8, 341.   DOI
63 Huang, J., Borensztajn, J. and Reddy, J. K. (2011) Hepatic lipid metabolism. In: Molecular Pathology of Liver Diseases. Molecular Pathology Library, Vol. 5 (S. Monga, Ed.), pp. 133-146. Springer, Boston.
64 Hur, K. Y. and Lee, M. (2015) Gut microbiota and metabolic disorders. Diabetes Metab. J. 39, 198-203.   DOI
65 Knopp, R. H. (1999) Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498-511.   DOI
66 Malhotra, A., Shafiq, N., Arora, A., Singh, M., Kumar, R. and Malhotra, S. (2014) Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst. Rev. 2014, CD001918.
67 Lesniak, W., Bala, M. M., Placzkiewicz-Jankowska, E., Topor-Madry, R., Jankowski, M., Sieradzki, J. and Banasiak, W.; ARETAEUS2 Study Group (2015) Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study. Cardiol. J. 22, 150-159.   DOI
68 Musso, G., Cassader, M., Paschetta, E. and Gambino, R. (2018) Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282-302.e8.   DOI
69 Nelson, R. H. (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care 40, 195-211.   DOI
70 Lee, C. H., Olson, P. and Evans, R. M. (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207.   DOI
71 Monnerie, S., Comte, B., Ziegler, D., Morais, J. A., Pujos- Guillot, E. and Gaudreau, P. (2020) Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: a systematic review. Sci. Rep. 10, 669.   DOI
72 Nagy, K. and Tiuca, I.-D. (2017) Importance of fatty acids in physiopathology of human body. In Fatty Acids. IntechOpen. doi: 10.5772/67407.   DOI
73 Lark, D. S., Fisher-Wellman, K. H. and Neufer, P. D. (2012) High-fat load: mechanism(s) of insulin resistance in skeletal muscle. Int. J. Obes. Suppl. 2, S31-S36.   DOI
74 Church, C., Horowitz, M. and Rodeheffer, M. (2012) WAT is a functional adipocyte? Adipocyte 1, 38-45.   DOI
75 Arslan, N. (2014) Obesity, fatty liver disease and intestinal microbiota. World J. Gastroenterol. 44, 16452-16463.   DOI
76 Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M. and Stein, E. A.; DESCARTES Investigators (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl J. Med. 370, 1809-1819.   DOI
77 Cani, P. D., Delzenne, N. M., Amar, J. and Burcelin, R. (2008) Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol. Biol. 56, 305-309.   DOI
78 Di Mauro, S., Trevisan, C. and Hays, A. (1980) Disorders of lipid metabolism in muscle. Muscle Nerve 3, 369-388.   DOI
79 Dogan, E. S. K., Dogan, B., Fentoglu, O. and Kirzioglu, F. Y. (2019) The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J. Periodontal Implant Sci. 49, 105-113.   DOI
80 Quispe, R., Hendrani, A., Baradaran-Noveiry, B., Martin, S., Brown, E., Kulkarni, K., Banach, M., Toth, P. P., Brinton, E. A., Jones, S. R. and Joshi, P. (2019) Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7. Arch. Med. Sci. 15, 1195-1202.   DOI
81 Reckless, J. P. D. and Lawrence, J. M. (2003) Hyperlipidemia (hyperlipidaemia). In Encyclopedia of Food Sciences and Nutrition (2nd ed.), pp. 3183-3192. Academic Press.
82 Rosca, M. G., Vazquez, E. J., Chen, Q., Kerner, J., Kern, T. S. and Hoppel, C. L. (2012) Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 61, 2074-2083.   DOI
83 Saudek, C. D. and Eder, H. A. (1979) Lipid metabolism in diabetes mellitus. Am. J. Med. 66, 843-852.   DOI
84 Schonfeld, G. (1990) Inherited disorders of lipid transport. Endocrinol. Metab. Clin. North Am. 19, 229-257.   DOI
85 Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Boren, J., Bruckert, E., Catapano, A. L., Descamps, O. S., Hovingh, G. K., Humphries, S. E., Kovanen, P. T., Masana, L., Pajukanta, P., Parhofer, K. G., Raal, F. J., Ray, K. K., Santos, R. D., Stalenhoef, A. F., Stroes, E., Taskinen, M. R., Tybjaerg-Hansen, A., Watts, G. F. and Wiklund, O.; European Atherosclerosis Society Consensus Panel (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2, 655-666.   DOI
86 Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., Rosa, R., Hermanowski-Vosatka, A., Wang, P. R., Zhang, D., Peterson, L., Detmers, P. A., Chao, Y. S. and Wright, S. D. (2001) Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21, 115-121.   DOI
87 Cena, H. and Calder, P. C. (2020) Defining a healthy diet: evidence for the role of contemporary dietary patterns in health and disease. Nutrients 12, 334.   DOI
88 Tocher, D. R. (2003) Metabolism and functions of lipids and fatty acids in teleost fish. Rev. Fish. Sci. 11, 107-184.   DOI
89 Uttaro, A. (2006) Biosynthesis of polyunsaturated fatty acids in lower eukaryotes. IUBMB Life 58, 563-571.   DOI
90 Wu, L. and Parhofer, K. G. (2014) Diabetic dyslipidemia. Metabolism 63, 1469-1479.   DOI